Abbott Laboratories (ABT)

44.71
0.76 1.73
NYSE : Health Care
Prev Close 43.95
Open 43.86
Day Low/High 43.83 / 44.85
52 Wk Low/High 36.76 / 45.84
Volume 8.62M
Avg Volume 6.54M
Exchange NYSE
Shares Outstanding 1.74B
Market Cap 77.58B
EPS 0.90
P/E Ratio 50.24
Div & Yield 1.06 (2.40%)

Latest News

Here Are Some of Congress' Favorite Stocks

Here Are Some of Congress' Favorite Stocks

While hard at work in Washington, a handful of members of Congress have also been busy trading stocks.

With Mother's Day Coming Up: Who Are the Best Employers for Working Moms?

With Mother's Day Coming Up: Who Are the Best Employers for Working Moms?

Female representation among the top 10% of earners at the NAFE top companies increased 2% to 41%, the highest since 2013.

Abbott Announces CE Mark For TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™

New Cardiac Ablation Catheter Integrates with 3D Mapping System to Advance the Treatment of Atrial Fibrillation

Cramer: These Sectors Look Bullish (Part III)

Cramer: These Sectors Look Bullish (Part III)

From Abbott Labs to Wynn, these names rate checking out.

Abbott Announces CE Mark And First Use Of The World's First Smartphone Compatible Insertable Cardiac Monitor

THE NEW CONFIRM RX™ ICM AUTOMATICALLY CAPTURES VITAL CARDIAC INFORMATION AND RELAYS DATA TO PHYSICIANS VIA THE MYMERLIN™ MOBILE APP ENABLING REMOTE MONITORING OF IRREGULAR HEART RHYTHMS

Cramer: There Are Powerful Themes in Several Bull Markets

Cramer: There Are Powerful Themes in Several Bull Markets

It's a wonder to me how split this market really is.

Abbott Announces National Reimbursement For FreeStyle® Libre In France, Providing Access To Revolutionary Technology For People With Diabetes

- FREESTYLE® LIBRE SYSTEM ELIMINATES ROUTINE FINGER STICKS(1) FOR GLUCOSE MEASUREMENTS AND REQUIRES NO FINGER STICKS FOR CALIBRATION

Good Medicine Makes for 3 Good Charts

Good Medicine Makes for 3 Good Charts

Medtronic, Abbott Labs and Becton Dickinson appear to be offering buying opportunities.

Abbott Introduces Science-Based Nutrition Drinks To Help Patients Have A Better Recovery From Surgery

- RESEARCH SHOWS THAT STAYING NOURISHED IN THE DAYS AND HOURS PRIOR TO A PROCEDURE CAN HELP PATIENTS PREPARE FOR AND RECOVER FROM SURGERY

Berkshire Hathaway, Southwest, Alaska Air: 'Mad Money' Lightning Round

Berkshire Hathaway, Southwest, Alaska Air: 'Mad Money' Lightning Round

Jim Cramer says he respects Buffett's judgment. Cramer's also bullish on some airline stocks.

Vive la U.S. Earnings: Cramer's 'Mad Money' Recap (Monday 4/24/17)

Vive la U.S. Earnings: Cramer's 'Mad Money' Recap (Monday 4/24/17)

Jim Cramer says a rally on French election results is fine, but don't forget great U.S. corporate earnings and merger activity.

Market Rally Rates a Meh

There is very little upside mo-mehn-tum.

Abbott CEO Upbeat Despite Ongoing Merger Headaches

Abbott CEO Upbeat Despite Ongoing Merger Headaches

Troubles at a plant acquired with St. Jude and continuing risks to closing the Alere deal linger over M&A spree.

Merger Challenges, FDA Concerns Dampen Abbott Gains Despite Strong First Quarter

Merger Challenges, FDA Concerns Dampen Abbott Gains Despite Strong First Quarter

Sales grew 29.7% in a year marked by acquisitions and new products, while comparable operations sales grew 3.2%.

S&P 500, Dow End at Session Lows After IBM Disappointment, Crude Slump

S&P 500, Dow End at Session Lows After IBM Disappointment, Crude Slump

Earlier market optimism faded as Wednesday wore on and a financials rally gave way to a selloff in Dow Jones Industrial Average component IBM and energy shares.

S&P 500 in Red as Energy's Slide Counters Morgan Stanley Gains

S&P 500 in Red as Energy's Slide Counters Morgan Stanley Gains

The S&P 500 hugs the flatline on Wednesday afternoon as a selloff in crude oil prices and energy shares counters better-than-expected earnings from Morgan Stanley.

Midday Report: Morgan Stanley Boosts Financials; IBM Drags Dow Into Red

Midday Report: Morgan Stanley Boosts Financials; IBM Drags Dow Into Red

Earnings take center stage again with a disappointment from IBM and a better-than-expected performance from Morgan Stanley dividing markets.

IBM Weighs on Dow, Morgan Stanley Gives Financials a Boost

IBM Weighs on Dow, Morgan Stanley Gives Financials a Boost

Earnings drive markets again on Wednesday with IBM dragging on the Dow Jones Industrial Average and Morgan Stanley driving financials, and broader markets, higher.

Market Recon: The Banks Trade Will Become a Yield Curve Watch

Market Recon: The Banks Trade Will Become a Yield Curve Watch

It really is that simple. Mr. and Ms. Market no longer trust the outlook for domestic economic growth.

Johnson & Johnson Sees Little Impact In Key Area Despite Pfizer Competition

Johnson & Johnson Sees Little Impact In Key Area Despite Pfizer Competition

Pfizer launched a Remicade biosimilar in November.

JNJ Shares Tick Up as Investors Eye Results for Three Business Lines

JNJ Shares Tick Up as Investors Eye Results for Three Business Lines

JNJ has been busy integrating newly acquired businesses.

Immunology Among Areas to Watch as Johnson & Johnson Gears Up to Report Results

Immunology Among Areas to Watch as Johnson & Johnson Gears Up to Report Results

JNJ's diabetes and oncology franchises will also be key when the New Brunswick, N.J.-based healthcare giant reports first-quarter numbers Tuesday morning.

Stocks That Are Changing Direction

Stocks That Are Changing Direction

These charts are showing bullish or bearish reversals.

Alere Stock Surging on Latest Abbott Agreement

Alere Stock Surging on Latest Abbott Agreement

Abbott will now pay a lower price to acquire Alere.

Cramer: These Stocks Look Like 'Easy Pickings'

Cramer: These Stocks Look Like 'Easy Pickings'

From Aetna to United Technologies, these names are hot.

Cramer: The Best Performers Show No Signs of Letting Up

Cramer: The Best Performers Show No Signs of Letting Up

Their overseas business has been carrying them.

Why AbbVie Will be an Incredible Money-Making Machine in an Overvalued Stock Market

Why AbbVie Will be an Incredible Money-Making Machine in an Overvalued Stock Market

The pharmaceutical giant has an attractive yield supported by double-digit earnings growth.